Comparative Pharmacology
Head-to-head clinical analysis: FURALAN versus MACRODANTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURALAN versus MACRODANTIN.
FURALAN vs MACRODANTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial acetyl-CoA carboxylase, interfere with bacterial cell wall synthesis, and damage bacterial DNA. It is bactericidal against a broad spectrum of gram-positive and gram-negative bacteria.
20 mg orally three times daily for 7 days.
100 mg orally twice daily for 5 days; for uncomplicated UTI. Route: oral. Frequency: twice daily.
None Documented
None Documented
Terminal elimination half-life is 8–12 hours in adults with normal renal function; this supports twice-daily dosing. In patients with creatinine clearance <30 mL/min, half-life may be prolonged to 20–30 hours, requiring dose adjustment.
20-60 minutes (prolonged in renal impairment, up to 8 hours in anuria)
Approximately 65–70% of an administered dose is excreted unchanged via renal glomerular filtration and tubular secretion; about 10–15% appears in bile as parent drug or glucuronide conjugate; up to 20% is eliminated in feces via unabsorbed fraction or biliary elimination.
Renal: 30-40% unchanged, Hepatic metabolism: 60-70% to inactive metabolites, Fecal: <1%
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective